Congress investigates how pharma middlemen affect drug prices
House Republicans are investigating pharmacy-benefit managers, middlemen in drug price negotiations, over whether they create unnecessary costs for prescription drugs.
Macroeconomy, inflation a 'driver' of risk preference at the CEO, board level: Mark Shafir
Citi Co-Head of Global Mergers and Acquisitions Mark Shafir discusses his outlook for the M&A and IPO market.
US needs to look at China as a 'serious threat': Rep. Anna Paulina Luna
Rep. Anna Paulina Luna, R-Fla., discusses the Biden administration's handling of the Chinese surveillance mission over the U.S., negotiations over the debt ceiling and Biden's claims that the GOP will cut Social Security and Medicare.
Artificial intelligence will be proliferated across all of Stryker: CEO Kevin Lobo
Stryker CEO Kevin Lobo discusses whether the expected surge in the orthopedics markets will drive sales in 2023 on 'The Claman Countdown.'
Ozempic, Wegovy help with weight loss but the rebound is real: Dr. Nicole Saphier
Fox News medical contributor Dr. Nicole Saphier discusses the dangers of using the diabetes drug Ozempic for weight loss on 'The Big Money Show.'
US Appeals Court sides with drugmakers on discount program
Drugmakers win battle in Third Circuit Court of Appeals over Health Resources and Services Administration, as courts decided HRSA went beyond the law with regulatory overreach.
Drug-shipping giant AmerisourceBergen gets 'fresh, bold' new name in Cencora
AmerisourceBergen chairman and CEO Steven Collis explains why the drug wholesale company is changing its name to Cencora on 'The Claman Countdown.'
The IRS is coming after middle America: Sen. Bill Hagerty
Sen. Bill Hagerty, R-Tenn., discusses the new GOP bill that would ban the IRS' $600 reporting requirement and reacts to claims that the GOP is targeting cuts to Social Security, Medicare, and Medicaid.
Johnson & Johnson fourth-quarter earnings down 25%
The company continues to see pressure on sales from staffing shortages at hospitals, which have limited growth in procedures using J&J products, while inflation has boosted expenses.
FDA rejects Lilly’s alzheimer’s drug candidate, seeks more data
Lilly said it would work with the FDA to evaluate the fastest pathway to get its Alzheimer’s drug to market after what it believes was a successful trial.
Proctor & Gamble raising prices as inflation persists
Proctor & Gamble is raising prices over the next few months, due to outside inflationary pressures and falling sales and revenue.
COVID vaccine mandates hurt the doctor-patient relationship: Dr. Frank Contacessa
MDVIP internist Dr. Frank Contacessa reacts to Gov. DeSantis moving to permanently ban COVID mandates in Florida on 'Varney & Co.'
Ozempic shortage a 'serious problem' for diabetics: Dr. Bob Lahita
St. Joseph Health Institute director Dr. Bob Lahita discusses how the Ozempic craze is causing issues for diabetics and addresses the rise in medical costs on 'Varney & Co.'
Wilbur Ross talks new investment
Former Secretary of Commerce Wilbur Ross announced a business combination agreement between Aprinoia Therapeutics and Ross Acquisition Corp to create a publicly listed company focused on neurodegenerative diseases.
Scientists reverse the aging process in mice, are humans next?
Dr. Marty Makary discusses new research that shows scientists have made inroads into reversing the aging process on 'Varney & Co.'
J&J slashes production of its unpopular COVID-19 shot
A partnership with rival Merck & Co. to help make the shots, forged at the urging of the U.S. government, hasn’t lived up to expectations. The companies are now engaged in arbitration.
Moderna CEO talks company transformation: 'This wasn’t going to be a one drug company'
Moderna CEO Stephane Bancel joins 'Mornings with Maria' to discuss how it transformed during the pandemic and its lawsuit against Pfizer.
Alphabet unit Verily to trim more than 200 jobs
Verily Life Sciences, formerly Google Life Sciences, a health care company and one of the largest under Google parent Alphabet's, umbrella, will lay off 15%.
FDA approves Biogen, Eisai Alzheimer’s drug
An Alzheimer’s drug from Biogen and Eisai has received accelerated approval from the Food and Drug Administration, the companies and agency announced Friday.
Shares of GE's health care spinoff make trading debut on Nasdaq
Trading of GE HealthCare Technologies shares kicked off Wednesday morning, marking its debut as an independent company from conglomerate General Electric.